icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
V0cFc54b8CpzjV5V